Genmab will acquire Merus Merus a Dutch biotechnology company, in an all-cash transaction worth around $8 billion. A Genmab subsidiary will pay $97 a share to complete the deal, which will give the Danish biotechnology company access to petosemtamab, Merus’ late-stage breakthrough cancer therapy. Merus stock, which closed Friday at $68.89, soared 38% to $94.91 in premarket trading Monday.
Continue Reading
View Comments
This Dutch Drugmaker’s Stock Is Jumping 38%. Here’s Why It’s Being Acquired.
Published 1 month ago
Sep 29, 2025 at 11:36 AM
Neutral
Auto